|開催日時：||2018年12月5日 18：00 ～ 19：00|
|所属：||1.Asia-Pacific Regional Medical Director, ViiV Healthcare Company
2.Global Medical Director, ViiV Healthcare company, Professor of Medicine, Voluntary Faculty, University of California, San Diego
|演題：||1.The role of integrase inhibitor and the resistance barrier for HIV infection, treatment and upcoming future
2.The impact of 2 drug regimen, Co-morbidities and Co-infection of HIV/HBV or HIV/HCV in the era of 2 drug regimen
1.The first topic of the day will be “Resistance in the era of 2-drug HIV integrase inhibitors-based ART” presented by Dr Wataru Sugiura. This presentation will review data on the barrier to resistance among HIV integrase inhibitors including data from 2-drug ART regimen trials. Ensuring the long-term efficacy of currently used drugs such as doltegravir is key, but the role of future antiretroviral agents may also be crucial to HIV treatment strategies in the future.
|世話人：||〇四柳 宏 (感染症分野)
俣野 哲朗 (エイズワクチン開発担当)